NIVOLUMAB AND HYALURONIDASE-NVHY

136 reported adverse events

Drug classes: Endoglycosidase [EPC] Programmed Death Receptor-1 Blocking Antibody [EPC]

These side effects are most commonly reported by patients taking NIVOLUMAB AND HYALURONIDASE-NVHY:

# Side effect Count
0 OFF LABEL USE 35
1 FATIGUE 12
2 RASH 12
3 PRODUCT STORAGE ERROR 11
4 ARTHRALGIA 10
5 DEATH 8
6 DIARRHOEA 7
7 CONSTIPATION 6
8 DECREASED APPETITE 6
9 PRODUCT DOSE OMISSION ISSUE 6
See all common reactions for NIVOLUMAB AND HYALURONIDASE-NVHY

NIVOLUMAB AND HYALURONIDASE-NVHY is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 PANCREATOGENOUS DIABETES 1 0.0154
1 CRANIAL NERVE PARALYSIS 1 0.0021
2 INGROWN HAIR 1 0.0014
3 CRANIAL NERVE DISORDER 1 0.0014
4 PRODUCT STORAGE ISSUE 5 0.0013
5 VASCULAR CALCIFICATION 1 0.0009
6 BENIGN NEOPLASM 1 0.0009
7 EYELID SKIN DRYNESS 1 0.0008
8 ADNEXA UTERI PAIN 1 0.0008
9 ABSCESS ORAL 1 0.0007
See all enriched reactions for NIVOLUMAB AND HYALURONIDASE-NVHY